The PRIDE study conducted by Janssen Pharmaceuticals, compared paliperidone palmitate (INVEGA SUSTENNA®) with commonly prescribed oral antipsychotics in adults with schizophrenia who had prior involvement with the criminal justice system. Results showed that INVEGA SUSTENNA® reduced the risk of treatment failure (including psychiatric hospitalization, arrest/incarceration, and discontinuation for safety/efficacy reasons). The benefits were seen both in patients with and without substance use disorders, and no new safety concerns were identified.
To read the full article, click here.
Contributor: Johnson & Johnson
Recent Posts
- Neurosurgery for psychiatric disorders: reviewing the past and charting the future in: Neurosurgical Focus Volume 54 Issue 2 (2023) Journals
- Synchronized cervical VNS with accelerated theta burst TMS for treatment resistant depression - Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation
- Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
